ClinicalTrials.gg
RecruitingNCT07022483Updated Oct 27, 2026

A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

A Phase 3 interventional study of Trastuzumab Deruxtecan and Chemotherapy in Endometrial Cancer, sponsored by Daiichi Sankyo. Recruiting at 86 sites in 15 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Oct 27, 2026First sites in Greece and IsraelPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
710
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 170 studies in Endometrial Neoplasms with a site in China — 98 open to participants now, 120 under way, 21 of them phase 3. Endometrial Neoplasms · China.

Planned enrollment
12th of 140
710 · median 115
Started
2025
with 29 others
Phase 3
20 of 170
9 open now
Primary completion
2030-02
later than 115 of 119 live
Registered
137th of 170
by date

Among the 170 studies in Endometrial Neoplasms with a site in China, this one is the 12th largest by planned enrollment of the 140 interventional ones that give a count, is one of 30 that started in 2025, is one of 20 in phase 3, reaches primary completion later than 115 of the 119 other live ones, and was the 137th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

98 of the 170 studies in Endometrial Neoplasms with a site in China are open now. Recruiting first, the newest first:

92 more — sign in →

All 98 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 170 studies in Endometrial Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.

Read the detailed description

This is a global, multicenter, open-label, phase 3 study to evaluate the efficacy and safety of T-DXd versus SoC chemotherapy with or without radiotherapy as adjuvant treatment in participants with HER2-expressing (IHC 3+/2+) endometrial cancer. Participants will be randomized 1:1 to either T-DXd or SoC chemotherapy. The primary objective will assess disease-free survival as assessed radiographically by BICR or by histopathologic confirmation of disease recurrence per local assessment.

T-DXd (Enhertu®) is a HER2 directed ADC composed of a humanized anti-HER2 IgG1 mAb with the same amino acid sequence as trastuzumab, which includes a plasma-stable, selectively cleavable linker and potent topoisomerase I inhibitor payload (a derivative of exatecan) that leverages the clinically validated DXd ADC technology.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • endometrial cancer
  • T-DXd
  • HER2
  • adjuvant treatment
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • Adults ≥18 years at the time the ICF is signed (Please follow local regulatory requirements if the legal age of consent for trial participation is >18 years old)
  • Has confirmed diagnosis of epithelial endometrial carcinoma. All histology's are allowed except for sarcomas (carcinosarcomas are allowed).
  • Is newly diagnosed FIGO 2023 Stage IIC (including Stage IICmp53abn) or Stage III Note: FIGO 2023 Stage IIC includes disease with aggressive histological types (aggressive histological types are composed of high-grade EECs (grade 3), serous, clear cell, undifferentiated, mixed, mesonephric-like, gastrointestinal mucinous type carcinomas, and carcinosarcomas) with any myometrial involvement. FIGO 2023 Stage III includes disease with local and/or regional spread of the tumor of any histological subtype.
  • Has -expression (IHC 3+/2+).
  • Has adequate archived tumor tissue sample available for assessment of HER2 status by central laboratory.

Key Exclusion Criteria

  • Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas. Adenosarcomas are also not allowed.
  • Has recurrent or FIGO 2023 Stage IV
  • Has residual tumor after surgery as determined by BICR assessment.
  • Is known to have a POLE mutation from an approved and/or validated local test, according to local regulations, if available
  • Has a medical history of MI within 6 months before randomization/enrollment, symptomatic CHF ( Class II to IV). Participants with troponin levels above at SCR (as defined by the manufacturer), and without any MI related symptoms should have a cardiologic consultation during SCR Period to rule out MI.
  • Has a prolongation to > 480 msec based on average of the SCR triplicate12-lead .
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the trial enrollment, severe asthma, severe , restrictive lung disease, pleural effusion, etc.) and any , connective tissue, or inflammatory disorder with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.), or prior pneumonectomy.
  • Has a history of (noninfectious) ILD/pneumonitis that required , has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at SCR.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
710 participants (estimated)

Study arms

  • Experimental
    Arm A: T-DXd

    Participants will receive T-DXd 5.4 mg/kg intravenously (IV) once every 3 weeks (Q3W) with or without \[optional\] radiotherapy

    Drug: Trastuzumab Deruxtecan

  • Active comparator
    Arm B: Standard of Care Chemotherapy

    Participants will receive carboplatin AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W, or AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W with or without \[optional\] radiotherapy or chemoradiotherapy (EBRT plus cisplatin \[as radiosensitizer\] 50 mg/m2

    Drug: Chemotherapy

Interventions

  • T-DXd will be administered at a dose of 5.4 mg/kg IV Q3W.

    Also known as: T-DXd, ENHERTU®

  • DrugChemotherapy

    Carboplatin AUC 5 or 6 and paclitaxel will be administered at a dose of 175 mg/m2 Q3W, or carboplatin AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W with or without radiation therapy.

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review or by Histopathologic Confirmation of Disease Recurrence per Local Assessment

    DFS will be assessed radiographically by BICR or by histopathologic confirmation of disease recurrence per local assessment.

    Time frame: From randomization to the first documented local regional recurrence, distant metastasis, or death due to any cause, whichever occurs first, up to approximately 51 months

Secondary outcomes

  1. Overall Survival

    Overall Survival is defined as the time interval from the date of randomization to the date of death due to any cause.

    Time frame: From randomization to the date of death due to any cause, approximately 63 months

07

Study locations

86 of 86 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Feb 2030, 52 months after the start.

Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's planned 52 months is close to that.

Primary completion moved once since we started tracking on Sep 25, 2026: Mar 2032 → Feb 2030, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 15, 2025
StartActual
Sep 30, 2025
Primary completionEst.
Feb 26, 2030was Mar 2032
CompletionEst.
Mar 23, 2032
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added — first sites in Greece and Israel
Show 11 added (4 United States, 2 Poland, 1 Argentina, 1 Greece, 1 Israel, 1 Italy, 1 Japan)
  • AdventHealth · Orlando, United States
  • Minnesota Oncology Hematology, P.A. · Coon Rapids, United States
  • Western Pennsylvania Hospital · Pittsburgh, United States
  • Texas Oncology - Bedford · Bedford, United States
  • Instituto Medico de la Fundacion Estudios Clinicos · Rosario, Argentina
  • IASO General Clinic · Marousi, Greece
  • Wolfson Medical Center · Holon, Israel
  • Azienda Ospedaliera Universitaria- Università degli Studi della Campania "Luigi Vanvitelli" · Naples, Italy
  • National Cancer Center Hospital · Chūōku, Japan
  • Bialostockie Centrum Onkologii im.M.Sklodowskiej-Curie · Bialystok, Poland
  • Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawla II w Siedlcach Sp z o o · Siedlce, Poland
Oct 27, 2026
Primary completion
Mar 23, 2032→Feb 26, 2030
Oct 27, 2026
Eligibility
4 criteria edited, 1 added
What changed in the criteria
  • EditedHas HER2-expression (IHC 3+/2+) per 2016 ASCO-CAP gastric cancer IHC scoring guidelines as confirmed by central laboratory testing.
  • EditedHas adequate archived tumor tissue sample (sample from surgery is strongly recommended) available for assessment of HER2 status by central laboratory.
  • EditedHas measurable residual tumor after surgery as determined by BICR assessment.
  • AddedHas a QTcF prolongation to > 480 msec based on average of the SCR triplicate12-lead ECG.
  • EditedHas a QTcF prolongation to > 480 msec based on average of the SCR triplicate12-lead ECG. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the trial enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion, etc.) and any autoimmune, connective tissue, or inflammatory disorder with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.), or prior pneumonectomy.
Oct 27, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedDisease-Free Survival (DFS) as Assessed by Blinded Independent Central Review or by Histopathologic Confirmation of Disease Recurrence per Local AssessmentTime frame: From randomization to the first documented local regional recurrence, distant metastasis, or death due to any cause, whichever occurs first, up to approximately 51 months
Oct 27, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameOverall SurvivalFrom randomization to the date of death due to any cause, up to approximately 63 months → From randomization to the date of death due to any cause, approximately 63 months
Oct 27, 2026
Title
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    11 sites added — first sites in Greece and Israel
    Show 11 added (4 United States, 2 Poland, 1 Argentina, 1 Greece, 1 Israel, 1 Italy, 1 Japan)
    • AdventHealth · Orlando, United States
    • Minnesota Oncology Hematology, P.A. · Coon Rapids, United States
    • Western Pennsylvania Hospital · Pittsburgh, United States
    • Texas Oncology - Bedford · Bedford, United States
    • Instituto Medico de la Fundacion Estudios Clinicos · Rosario, Argentina
    • IASO General Clinic · Marousi, Greece
    • Wolfson Medical Center · Holon, Israel
    • Azienda Ospedaliera Universitaria- Università degli Studi della Campania "Luigi Vanvitelli" · Naples, Italy
    • National Cancer Center Hospital · Chūōku, Japan
    • Bialostockie Centrum Onkologii im.M.Sklodowskiej-Curie · Bialystok, Poland
    • Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawla II w Siedlcach Sp z o o · Siedlce, Poland
    Primary completion Mar 23, 2032→Feb 26, 2030
    Eligibility 4 criteria edited, 1 added
    What changed in the criteria
    • EditedHas HER2-expression (IHC 3+/2+) per 2016 ASCO-CAP gastric cancer IHC scoring guidelines as confirmed by central laboratory testing.
    • EditedHas adequate archived tumor tissue sample (sample from surgery is strongly recommended) available for assessment of HER2 status by central laboratory.
    • EditedHas measurable residual tumor after surgery as determined by BICR assessment.
    • AddedHas a QTcF prolongation to > 480 msec based on average of the SCR triplicate12-lead ECG.
    • EditedHas a QTcF prolongation to > 480 msec based on average of the SCR triplicate12-lead ECG. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the trial enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion, etc.) and any autoimmune, connective tissue, or inflammatory disorder with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.), or prior pneumonectomy.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedDisease-Free Survival (DFS) as Assessed by Blinded Independent Central Review or by Histopathologic Confirmation of Disease Recurrence per Local AssessmentTime frame: From randomization to the first documented local regional recurrence, distant metastasis, or death due to any cause, whichever occurs first, up to approximately 51 months
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameOverall SurvivalFrom randomization to the date of death due to any cause, up to approximately 63 months → From randomization to the date of death due to any cause, approximately 63 months
    Title A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
    + 4 other changes: index terms, verification date, conditions and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07022483
Lead sponsor
Daiichi Sankyo
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Sep 30, 2025
Primary completion
Feb 26, 2030 (estimated)
Completion
Mar 23, 2032 (estimated)
Last update
Oct 27, 2026

Study contacts

Contact for Trial Information
Contact
CTRinfo_us@daiichisankyo.com
908-992-6400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion